Donor immune cells show promise against returning blood cancers

This early-phase study tests a new treatment for people with certain blood cancers (lymphoma or leukemia) that have returned after a stem cell transplant. Researchers take immune cells called T cells from the original stem cell donor, modify them to recognize and attack cancer cells (using a special receptor called CAR), and give them to the patient. The main goals are to find the safest dose and to see if this approach can control the cancer without causing severe side effects.